GAP President John Dwyer John Dwyer with ADDF's Mark Roithmayr and Lilly's Scott Shortenhaus enjoyed the 14TH Annual Great Ladies Luncheon and Fashion Show in support of our partners and great friends at Alzheimer's Drug Discovery Foundation

Congratulations to Venkat Shastri, PhD, CEO of DxA-funded ALZpath, for being named a 2024 TIME 100 Health Innovator! Learn more about the company's ptau217 #BloodTest , which is equally as accurate as the gold standard diagnostics for #Alzheimers here: bit.ly/3QyxGVD

A new study argues that the APOE4 gene—which has long been viewed as a major #genetic risk factor for #Alzheimers —may cause a distinct form of the disease. Our CSO, Howard Fillit, MD, spoke with STAT about how the study will affect future research & care: bit.ly/4a4U3Zz

What if speech could transform Alzheimer’s detection? Last month at #ADPD24 , Rhoda Au talked about Alzheimer's Drug Discovery Foundation's SpeechDx, an initiative utilizing high-quality, harmonized voice and clinical data, speech biomarkers for ADRD detection. Learn more:
bit.ly/4bg81J2

DxA-funded RetiSpec has announced a new investment & partnership with Topcon Healthcare. Once commercialized, the partners will bring RetiSpec's clinically-validated, #AI -powered eye #diagnostic that helps physicians predict #amyloid burden to market: prn.to/3wkRYeh

Eliminating Alzheimer’s requires a global, diversified effort. In a recent Scientific American article, Bill Gates and key experts discuss how #ADRD research is reaching a tipping point through open data, accessible solutions, and health system preparedness.
bit.ly/3Qq4LTA

Friend of the ADDF Jeffrey Cummings released his 2024 #Alzheimers clinical trials report, offering a complete snapshot of the Phase 1-3 drugs in development—73% of which are targeting the various #novel pathways guided by the #BiologyOfAging . Read here: bit.ly/3UFFqrb

Apply now for the ADDF-Harrington Scholar award and receive up to $600k in funding, drug development support, and expert advice to advance your Alzheimer’s research. Don’t miss this opportunity to make an impact! #Alzheimers #ResearchFunding Alzheimer's Drug Discovery Foundation bit.ly/3PRv9E1

Our CEO, Mark Roithmayr, spoke today at #ADI2024 on how the ADDF's unique #VenturePhilanthropy model helps accelerate #Alzheimer 's drug discovery & development, discussing the #BiologyOfAging & expressing optimism that recent momentum in the space will usher in a new era of care.

World Dementia Council Mark Roithmayr Alzheimer's Drug Discovery Foundation ADI Fantastic to see and sorry to miss this. Mark Roithmayr is such a brilliant leader in this space and all of us Alzheimer's Research UK love working with him 🤩

The final plenary of #ADI2024 is underway. Mark Roithmayr starts the session highlighting the power of investment and the current state of the Alzheimer’s drug discovery pipeline.

I am thrilled to share that we presented the latest 2024 Alzheimer’s Disease Drug Development pipeline with our fabulous colleague Jeffrey Cummings Thanks The National Institute on Aging (NIA) Alzheimer's Drug Discovery Foundation alz-journals.onlinelibrary.wiley.com/doi/full/10.10…

#BloodTests will likely replace the gold standard #Alzheimer 's tests due to their #Accessibility & #Scalability . Read how the #FDA granted Lilly & Roche a breakthrough designation to accelerate the development of their pTau217 blood test in FierceBiotech: bit.ly/4da17Hf

In a special issue of Scientific American developed by our friends at Davos Alzheimer’s Collaborative, Bill Gates discusses the new era of #Alzheimers research & how partnering with the ADDF to launch the #DxA has helped revolutionize the diagnostic landscape. Read his Q&A here: bit.ly/3JxpbGk

Vaccinex anticipates completing its planned treatment of patients w/ mild #AlzheimersDisease in the Ph 1b/2 SIGNAL-AD trial of pepinemab in June with topline data expected in Q3 2024. The study was funded in part by Alzheimer's Drug Discovery Foundation & a grant from Alzheimer's Association bit.ly/3meTfeg

#WilliamsEquities had the honor of attending the Seventh Annual Memories Matter fundraiser at the American Museum of Natural History, hosted by Alzheimer's Drug Discovery Foundation. We are proud to stand with the #ADDF in their mission to advance Alzheimer's research and treatment.

#WilliamsEquities #MemoriesMatter #NYRE

RFP of the Day: Alzheimer's Drug Discovery Foundation invites LOIs for Neuroimaging and CSF Biomarker Program; grants of up to $600,000 will be awarded in support of research with the potential to develop and validate biomarkers for which there is a clear clinical need bit.ly/3U5YP3d

We're in a modern era #Alzheimers research bringing new hope to patients. In Scientific American, Bill Gates shares how his partnership with the #DiagnosticsAccelerator , which has catalyzed $60M into 58 biomarker programs, is paving the way for a more timely diagnosis
bit.ly/3xNaYSV

Innovative researchers wanted! The ADDF-Harrington Scholar Award offers funding, project management support, and regulatory assistance for breakthrough discoveries targeting #Alzheimers disease and related dementias. Alzheimer's Drug Discovery Foundation bit.ly/3PRv9E1

The #Alzheimers diagnostics landscape is rapidly evolving, and our CSO Howard Fillit, MD connected with C&EN (Chemical & Engineering News) to discuss the DxA, its funding of blood-based #biomarkers & #digital #diagnostic tools, and predictions for the future of #BloodTests . Read more here: bit.ly/3JaGZXR